Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.65 |
| ▸ | HINT1 | P49773 | 5/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 2/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.51 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.51 |
| ▸ | PNP | P00491 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26294891 | 0.88 | HINT1 (0.56) | ADORA3HINT1NT5EADORA2AADORA2B | |
| SCHEMBL5360770 | 0.88 | HINT1 (0.56) | ADORA3HINT1NT5EADORA2AADORA2B | |
| 2'-Beta-Methyl-Guanosine SCHEMBL383785 | 0.88 | HINT1 (0.75) | ADORA3HINT1NT5EGSK3ARPS6KA3 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL116165 | 0.88 | HINT1 (0.75) | ADORA3HINT1NT5EGSK3ARPS6KA3 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL14178410 | 0.88 | HINT1 (0.75) | ADORA3HINT1NT5EGSK3ARPS6KA3 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL11965261 | 0.88 | HINT1 (0.75) | ADORA3HINT1NT5EGSK3ARPS6KA3 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL15338533 | 0.88 | HINT1 (0.75) | ADORA3HINT1NT5EGSK3ARPS6KA3 | |
| Thioguanosine SCHEMBL1981035 | 0.87 | LMNA (0.62) | ADORA3NT5EADORA2AADORA2B | |
| Thioguanosine SCHEMBL4527562 | 0.87 | LMNA (0.62) | ADORA3NT5EADORA2AADORA2B | |
| Thioguanosine SCHEMBL230740 | 0.87 | LMNA (0.62) | ADORA3NT5EADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 599 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2025151711-A1 | NUCLEIC ACID VACCINES TARGETING METHANOGENS | Arkea Bio Corp. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4554616-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2024233308-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| WO-2024012270-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | 传信生物医药(苏州)有限公司 | 2024-01-18 | — | — | WO | claimed |
| WO-2024015366-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2024-01-18 | — | — | WO | claimed |
| US-20240009291-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. | 2024-01-11 | — | — | US | claimed |
| WO-2023178182-A1 | COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION | 10X GENOMICS, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| US-11090332-B2 | Antigen specific mRNA cellular cancer vaccines | Regen BioPharma, Inc. (US) | 2021-08-17 | — | — | US | claimed |
| EP-3423595-A1 | RNA ANALYSIS BY TOTAL HYDROLYSIS | CureVac AG (DE) | 2019-01-09 | — | — | EP | claimed |
| EP-2833894-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF COSMETIC PROTEINS AND PEPTIDES | Moderna Therapeutics, Inc. (US) | 2015-02-11 | — | — | EP | claimed |
| EP-2755693-A2 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | Moderna Therapeutics, Inc. (US) | 2014-07-23 | — | — | EP | claimed |
| EP-2710136-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF FOR NON-HUMAN VERTEBRATES | Moderna Therapeutics, Inc. (US) | 2014-03-26 | — | — | EP | claimed |
| EP-2691101-A2 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | Moderna Therapeutics, Inc. (US) | 2014-02-05 | — | — | EP | claimed |
| WO-2013151671-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF COSMETIC PROTEINS AND PEPTIDES | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | claimed |
| WO-2013151672-A2 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | claimed |
| WO-2013151736-A2 | IN VIVO PRODUCTION OF PROTEINS | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | claimed |
| WO-2013039861-A2 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | modeRNA Therapeutics (US) | 2013-03-21 | — | — | WO | claimed |
| WO-2012158736-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF FOR NON-HUMAN VERTEBRATES | modeRNA Therapeutics (US) | 2012-11-22 | — | — | WO | claimed |
| WO-2012135805-A2 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | modeRNA Therapeutics (US) | 2012-10-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009291-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | MT-CO2, CYB5R3, COX5A | ADORA3 1579/4885HINT1 1972/4885NT5E 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.